Stock CANF CAN-FITE BIOPHARMA LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Can-Fite BioPharma Ltd. Nyse

Equities

CANF

US13471N3008

Market Closed - Nyse
Other stock markets
 16:00:00 2024-07-17 EDT 		5-day change 1st Jan Change
3.64 USD -0.55% Intraday chart for Can-Fite BioPharma Ltd. +15.19% +65.45%
07-01 Can-Fite BioPharma Ltd. Announces Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson CI
06-28 Can-Fite BioPharma Ltd. Announces Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Vetbiolix CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Can Fite BioPharma : Fite Presentation
PU
Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson
AQ
Can-Fite BioPharma Ltd. Announces Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson
CI
Can Fite BioPharma : Other Report or Announcement
PU
Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix
BU
Can-Fite BioPharma Ltd. Announces Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Vetbiolix
CI
Can Fite BioPharma : Other Report or Announcement
PU
Can Fite BioPharma : Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
PU
Can-Fite Announces Breakthrough Findings Demonstrate Namodenoson Anti-Cancer and Protective Effect Mechanism in the Liver
CI
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
BU
Can Fite BioPharma : Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study
PU
Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study
BU
Can-Fite Biopharma Ltd. Receives IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study
CI
Transcript : Can-Fite BioPharma Ltd. - Special Call
Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study
BU
Can-Fite Biopharma Ltd. Updates on Its Advanced Liver Cancer Pivotal Phase 3 Study
CI
Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases
BU
Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024
BU
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6
BU
Can Fite BioPharma : Immediate Report of Meeting
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CANF Stock
  4. CANF Stock
  5. News Can-Fite BioPharma Ltd.